Literature DB >> 10733930

Sepsis-induced muscle proteolysis is prevented by a proteasome inhibitor in vivo.

D Fischer1, G Gang, T Pritts, P O Hasselgren.   

Abstract

Sepsis-induced muscle proteolysis mainly reflects ubiquitin-proteasome-dependent protein degradation. The effect of in vivo administration of a proteasome inhibitor on muscle protein breakdown during sepsis is not known. We treated rats with the proteasome inhibitor N-benzyloxycarbonyl-Ile-Glu-(O-t-butyl)-Ala-leucinal (PSI) or corresponding volume of vehicle i.p. 2 h before sham-operation or induction of sepsis by cecal ligation and puncture. The sepsis-induced increase in total and myofibrillar muscle protein breakdown was inhibited in rats treated in vivo with PSI and a maximal effect was seen following 15 mg/kg of the proteasome inhibitor. Results from in vitro experiments in which incubated muscles were treated with 100 microM PSI suggest that the drug has a direct effect on muscle and that the effect is specific for the proteasome. The results are important because they suggest that it may be possible to prevent or improve the cachectic response in skeletal muscle during sepsis by treatment with a proteasome inhibitor. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733930     DOI: 10.1006/bbrc.2000.2398

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  The dose-dependent effects of endotoxin on protein metabolism in two types of rat skeletal muscle.

Authors:  Miroslav Kovarik; Tomas Muthny; Ludek Sispera; Milan Holecek
Journal:  J Physiol Biochem       Date:  2012-02-07       Impact factor: 4.158

2.  Effects of β-hydroxy-β-methylbutyrate treatment in different types of skeletal muscle of intact and septic rats.

Authors:  Miroslav Kovarik; Tomas Muthny; Ludek Sispera; Milan Holecek
Journal:  J Physiol Biochem       Date:  2010-08-20       Impact factor: 4.158

3.  Mechanism of ICU-acquired weakness: skeletal muscle loss in critical illness.

Authors:  Jane Batt; Margaret Herridge; Claudia Dos Santos
Journal:  Intensive Care Med       Date:  2017-03-10       Impact factor: 17.440

Review 4.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

5.  Distinct protein degradation profiles are induced by different disuse models of skeletal muscle atrophy.

Authors:  Peter Bialek; Carl Morris; Jascha Parkington; Michael St Andre; Jane Owens; Paul Yaworsky; Howard Seeherman; Scott A Jelinsky
Journal:  Physiol Genomics       Date:  2011-07-26       Impact factor: 3.107

Review 6.  Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation.

Authors:  P O Hasselgren; J E Fischer
Journal:  Ann Surg       Date:  2001-01       Impact factor: 12.969

7.  Acute alcohol intoxication increases atrogin-1 and MuRF1 mRNA without increasing proteolysis in skeletal muscle.

Authors:  Thomas C Vary; Robert A Frost; Charles H Lang
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-04-09       Impact factor: 3.619

Review 8.  F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.

Authors:  Ammar Sukari; Irfana Muqbil; Ramzi M Mohammad; Philip A Philip; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2016-01-21       Impact factor: 15.707

9.  Regulation of caspase-3 activity by insulin in skeletal muscle cells involves both PI3-kinase and MEK-1/2.

Authors:  Yongmei Gao; Ronald Ordas; Janet D Klein; S Russ Price
Journal:  J Appl Physiol (1985)       Date:  2008-10-02

10.  Effects of endotoxaemia on protein metabolism in rat fast-twitch skeletal muscle and myocardium.

Authors:  Andrew J Murton; Nima Alamdari; Sheila M Gardiner; Dumitru Constantin-Teodosiu; Robert Layfield; Terence Bennett; Paul L Greenhaff
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.